только для медицинских специалистов

Консультант врача

Электронная медицинская библиотека

Раздел 4 / 8
Страница 1 / 1

Список литературы

  1. Воробьев АИ, editor. Руководство по гематологии: в 3 т. М.: “Ниюдиамед”; 2005.
  2. Peyvandi F, Palla R, Menegatti M, Siboni SM, Halimeh S, Faeser B, et al. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: Results from the European Network of Rare Bleeding Disorders. J Thromb Haemost 2012;10:615–21. https://doi.org/10.1111/j.1538-7836.2012.04653.x.
  3. Acharya SS, Coughlin A, Dimichele DM, Jublirer SJ, Arden D, Anderson V, et al. Rare bleeding disorder registry: Deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost 2004;2:248–56. https://doi.org/10.1111/j.1538-7836.2003.t01-1-00553.x.
  4. Herrmann FH, Auerswald G, Ruiz-Saez A, Navarrete M, Pollmann H, Lopaciuk S, et al. Factor X deficiency: Clinical manifestation of 102 subjects from Europe and Latin America with mutations in the factor 10 gene. Haemophilia 2006;12:479–89. https://doi.org/10.1111/j.1365-2516.2006.01303.x.
  5. Herrmann FH, Wulff K, Auerswald G, Schulman S, Astermark J, Batorova A, et al. Factor VII deficiency: Clinical manifestation of 717 subjects from Europe and Latin America with mutations in the factor 7 gene. Haemophilia 2009;15:267–80. https://doi.org/10.1111/j.1365-2516.2008.01910.x.
  6. Ivaskevicius V, Seitz R, Kohler HP, Schroeder V, Muszbek L, Ariens RAS, et al. International registry on factor XIII deficiency: a basis formed mostly on European data. Thromb Haemost 2007;97:914–21.
  7. BERNARDI F, DOLCE A, PINOTTI M, SHAPIRO AD, SANTAGOSTINO E, PEYVANDI F, et al. Major differences in bleeding symptoms between factor VII deficiency and hemophilia B. J Thromb Haemost 2009;7:774–9. https://doi.org/10.1111/j.1538-7836.2009.03329.x.
  8. Mumford AD, Ackroyd S, Alikhan R, Bowles L, Chowdary P, Grainger J, et al. Guideline for the diagnosis and management of the rare coagulation disorders: A United Kingdom haemophilia centre doctors’ organization guideline on behalf of the British committee for standards in haematology. Br J Haematol 2014;167:304–26.
  9. Peyvandi F, Di Michele D, Bolton-Maggs PHB, Lee CA, Tripodi A, Srivastava A. Classification of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severity. J Thromb Haemost 2012;10:1938–43. https://doi.org/10.1111/j.1538-7836.2012.04844.x.
  10. Баркаган ЗС, Момот АП. Диагностика и контролируемая терапия нарушений гемостаза. 2001.
  11. Давыдкин ИЛ, Момот АП, Зозуля НИ, Ройтман ЕВ, editors. Основы клинической гемостазиологии и гемореологии: монография. Самара: ООО ИПК «Самарская Губерния»; 2017.
  12. Akhavan S, Mannucci PM, Lak M, Mancuso G, Mazzucconi MG, Rocino A, et al. Identification and three-dimensional structural analysis of nine novel mutations in patients with prothrombin deficiency. Thromb Haemost 2000;84:989–97. https://doi.org/10.1055/s-0037-1614161.
  13. Bolton-Maggs PHB, Perry DJ, Chalmers EA, Parapia LA, Wilde JT, Williams MD, et al. The rare coagulation disorders - Review with guidelines for management from the United Kingdom Haemophilia Centre Doctors’ Organisation. Haemophilia 2004;10:593–628. https://doi.org/10.1111/j.1365-2516.2004.00944.x.
  14. GIROLAMI A, VETTORE S, SCARPARO P, LOMBARDI AM. Persistent validity of a classification of congenital factor X defects based on clotting, chromogenic and immunological assays even in the molecular biology era. Haemophilia 2011;17:17–20. https://doi.org/10.1111/j.1365-2516.2010.02328.x.
  15. KARIMI M, VAFAFAR A, HAGHPANAH S, PAYANDEH M, ESHGHI P, HOOFAR H, et al. Efficacy of prophylaxis and genotype-phenotype correlation in patients with severe Factor X deficiency in Iran. Haemophilia 2012;18:211–5. https://doi.org/10.1111/j.1365-2516.2011.02635.x.
  16. Mariani G, Herrmann FH, Dolce A, Batorova A, Etro D, Peyvandi F, et al. Clinical phenotypes and factor VII genotype in congenital factor VII deficiency. Thromb Haemost 2005;93:481–7. https://doi.org/10.1160/TH04-10-0650.
  17. Момот АП. Принципы и алгоритмы клинико-лабораторной диагностики. СПб: ФормаТ; 2006.
  18. Добровольский АБ, Косырев АБ. Протромбиновый тест: Методика выполнения и клиническое значение. Ассоциация Медицинской Лабораторной Диагностики Информационный Бюллетень 1995;2:34–8.
  19. BROWN DL, KOUIDES PA. Diagnosis and treatment of inherited factor X deficiency. Haemophilia 2008;14:1176–82. https://doi.org/10.1111/j.1365-2516.2008.01856.x.
  20. Lancellotti S, Basso M, De Cristofaro R. Congenital prothrombin deficiency: An update. Semin Thromb Hemost 2013;39:596–606. https://doi.org/10.1055/s-0033-1348948.
  21. Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood 2004;104:1243–52. https://doi.org/10.1182/blood-2004-02-0595.
  22. Di Minno MND, Dolce A, Mariani G. Bleeding symptoms at disease presentation and prediction of ensuing bleeding in inherited FVII deficiency. Thromb Haemost 2013;109:1051–9. https://doi.org/10.1160/TH12-10-0740.
  23. Giansily-Blaizot M, Marty S, Chen SWW, Pellequer JL, Schved JF. Is the coexistence of thromboembolic events and Factor VII deficiency fortuitous? Thromb Res 2012;130. https://doi.org/10.1016/j.thromres.2012.08.273.
  24. Keeling D, Tait C, Makris M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia 2008;14:671–84. https://doi.org/10.1111/j.1365-2516.2008.01695.x.
  25. Girolami A, Vettore S, Ruzzon E, Marinis GB De, Fabris F. Rare and unusual bleeding manifestations in congenital bleeding disorders: An annotated review. Clin Appl Thromb 2012;18:121–7. https://doi.org/10.1177/1076029611416638.
  26. Ушакова ОЕ, Нечипуренко ДЮ, Бутылин АА, Пантелеев МА. Применение проточных систем в лабораторной диагностике для интегральной оценки системы гемостаза. Вопросы Гематологии / Онкологии и Иммунопатологии в Педиатрии 2018;17:117–29.
  27. Franchini M, Lippi G. Prothrombin complex concentrates: An update. Blood Transfus 2010;8:149–54. https://doi.org/10.2450/2010.0149-09.
  28. Menegatti M, Peyvandi F. Treatment of rare factor deficiencies other than hemophilia. Blood 2019;133:415–24. https://doi.org/10.1182/blood-2018-06-820738.
  29. Dorgalaleh A, Tabibian S, Hosseini MS, Shams M. Pharmacological management of rare coagulation factor deficiencies besides hemophilia. Expert Rev Hematol 2020;13. https://doi.org/10.1080/17474086.2020.1796622.
  30. Peyvandi F, Menegatti M. Treatment of rare factor deficiencies in 2016. Hematol Am Soc Hematol Educ Progr 2016;2016:663–9. https://doi.org/10.1182/ASHEDUCATION-2016.1.663.
  31. TODD T, J PERRY D. A review of long-term prophylaxis in the rare inherited coagulation factor deficiencies. Haemophilia 2009;16:569–83. https://doi.org/10.1111/j.1365-2516.2009.02118.x.
  32. Tengborn L, Blombäck M, Berntorp E. Tranexamic acid - An old drug still going strong and making a revival. Thromb Res 2015;135:231–42. https://doi.org/10.1016/j.thromres.2014.11.012.
  33. Berrettini M, Mariani G, Schiavoni M, Rocino A, Paolantonio T Di, Longo G, et al. Pharmacokinetic evaluation of recombinant, activated factor VII in patients with inherited factor VII deficiency. vol. 86. 2001. https://doi.org/10.3324/%X.
  34. Mariani G, Konkle BA, Ingerslev J. Congenital factor VII deficiency: Therapy with recombinant activated factor VII - A critical appraisal. Haemophilia 2006;12:19–27. https://doi.org/10.1111/j.1365-2516.2006.01180.x.
  35. Mariani G, Dolce A, Batorova A, Auerswald G, Schved JF, Siragusa S, et al. Recombinant, activated factor VII for surgery in factor VII deficiency: A prospective evaluation - the surgical STER. Br J Haematol 2011;152:340–6. https://doi.org/10.1111/j.1365-2141.2010.08287.x.
  36. Mariani G, Napolitano M, Dolce A, Garrido RP, Batorova A, Karimi M, et al. Replacement therapy for bleeding episodes in factor VII deficiency. Thromb Haemost 2013;109:238–47. https://doi.org/10.1160/TH12-07-0476.
  37. Napolitano M, Giansily-Blaizot M, Dolce A, Schved JF, Auerswald G, Ingerslev J, et al. Prophylaxis in congenital factor VII deficiency: Indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER). Haematologica 2013;98:538–44. https://doi.org/10.3324/haematol.2012.074039.
  38. Mariani G, Dolce A, Marchetti G, Bernardi F. Clinical picture and management of congenital factor VII deficiency. Haemophilia 2004;10 Suppl 4:180–3. https://doi.org/10.1111/J.1365-2516.2004.00990.X.
  39. Salcioglu Z, Akcay A, Sen HS, Aydogan G, Akici F, Tugcu D, et al. Factor VII deficiency: a single-center experience. Clin Appl Thromb Hemost 2012;18:588–93. https://doi.org/10.1177/1076029611435091.
  40. McMahon C, Smith J, Goonan C, Byrne M, Smith OP. The role of primary prophylactic factor replacement therapy in children with severe factor X deficiency. Br J Haematol 2002;119:789–91. https://doi.org/10.1046/j.1365-2141.2002.03932.x.
  41. Суворова АВ, Абраменко ЛИ, Курденко ИВ, Назарова РВ. Патология системы гемостаза у новорожденных. Барнаул: 2004.
  42. Шабалов НП. Гемостаз в динамике первой недели жизни как отражение механизмов адаптации к внеутробной жизни новорожденных. Педиатрия 2000;3:84–91.
  43. BOWLES L, BAKER K, KHAIR K, MATHIAS M, LIESNER R. Prophylaxis with prothrombin complex concentrate in four children with severe congenital factor X deficiency. Haemophilia 2009;15:401–3. https://doi.org/10.1111/j.1365-2516.2008.01878.x.
  44. Barillari G, Pasca S, Gonano N, Daminato R. Prothrombin complex concentrate such as therapy and prophylaxis in factor X-deficient patient (Friuli Variant). Clin Appl Thromb 2011;17:332–6. https://doi.org/10.1177/1076029610365331.
  45. Kouides PA, Kulzer L. Prophylactic treatment of severe factor X deficiency with prothrombin complex concentrate. Haemophilia 2001;7:220–3. https://doi.org/10.1046/j.1365-2516.2001.00485.x.
  46. Uprichard J, Perry DJ. Factor X deficiency. Blood Rev 2002;16:97–110. https://doi.org/10.1054/blre.2002.0191.
  47. Van Veen JJ, Hampton KK, Maclean R, Fairlie F, Makris M. Blood product support for delivery in severe factor X deficiency: The use of thrombin generation to guide therapy. Blood Transfus 2007;5:204–9. https://doi.org/10.2450/2007.0023-07.
  48. Viswabandya A, Baidya S, Nair SC, Abraham A, George B, Mathews V, et al. Correlating clinical manifestations with factor levels in rare bleeding disorders: A report from Southern India. Haemophilia 2012;18. https://doi.org/10.1111/j.1365-2516.2011.02730.x.
  49. KADIR R, CHI C, BOLTON-MAGGS P. Pregnancy and rare bleeding disorders. Haemophilia 2009;15:990–1005. https://doi.org/10.1111/j.1365-2516.2009.01984.x.
  50. Baumann Kreuziger LM, Morton CT, Reding MT. Is prophylaxis required for delivery in women with factor VII deficiency? Haemophilia 2013;19:827–32. https://doi.org/10.1111/hae.12167.
  51. Kulkarni AA, Lee CA, Kadir RA. Pregnancy in women with congenital factor VII deficiency. Haemophilia 2006;12:413–6. https://doi.org/10.1111/j.1365-2516.2006.01287.x.
  52. Beksaç MS, Atak Z, Özlü T. Severe factor X deficiency in a twin pregnancy. Arch Gynecol Obstet 2010;281:151–2. https://doi.org/10.1007/s00404-009-1090-4.